Results 101 to 110 of about 32,890 (266)

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young, Jennifer E. Murphy, Mallory Chavannes, Jennifer L. Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses, Sandra C. Kim   +10 more
wiley   +1 more source

Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study

Journal of Dermatological Treatment
Background The advent of biosimilars may increase the frequency of dose escalation with biologics in psoriasis.Objective To explore the frequency and outcomes of dose escalation with adalimumab etanercept, and ustekinumab.Methods Data were extracted from
Axel Svedbom, Christina Wennerström, Fredrik Hjelm, Anna Tjärnlund, Mona Ståhle   +4 more
doaj   +1 more source

Two Minimal Clinically Important Difference (2MCID) : A New Twist on an Old Concept [PDF]

, 2018
This work is open access licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, https://creativecommons.org/licenses/by-nc/4.0/Peer ...
Ali, Faraz M, Finlay, Andrew, Salek, M Sam   +2 more
core   +5 more sources

Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains
Jane Oba, Carlos Walter Sobrado, Elizete Aparecida Lomazi, Mariana Deboni, Michela Cynthia da Rocha Marmo, Vanessa Adriana Scheeffer, Silvio da Rocha Carvalho, Adérson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Carlos Frederico Sparapan Marques, Eytan Wine, Artur Figueiredo Delgado, Clovis Artur Almeida da Silva Full   +12 more
wiley   +1 more source

A Review of Ankylosing Spondylitis [PDF]

, 2017
Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of peripheral joints among other symptoms.
Owen, Hannah L
core   +1 more source

Long‐term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Acute severe colitis (ASC) is a frequent and severe complication of ulcerative colitis (UC) with a high risk of colectomy. Effects of immunosuppressants and anti–tumor necrosis factor (anti‐TNF) agents on the risk of colectomy remain debated. We wished to study the evolution of French pediatric‐onset UC patients after ASC.
Manon Cochet, Agathe Beauvais, Frank Ruemmele, Raphael Enaud, Thierry Lamireau, Rémi Duclaux‐Loras, Claire Dupont, Stéphanie Willot, Laure Bridoux‐Henno, Georges Dimitrov, Julie Lemale, Vincent Guinard‐Samuel, Valérie Bertrand, Anne Breton, Christine Martinez Vinson, Stéphanie Coopman, Delphine Ley, Bénédicte Pigneur, and the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du tube Digestif (GETAID) pédiatrique   +18 more
wiley   +1 more source

Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature

BMC Gastroenterology, 2017
Background Ustekinumab is a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and 23 which is involved in the pathogenesis of several inflammatory diseases.
C. Venturin, S. Nancey, P. Danion, M. Uzzan, M. Chauvenet, C. Bergoin, X. Roblin, B. Flourié, G. Boschetti   +8 more
doaj   +1 more source

Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies [PDF]

, 2016
Scalp psoriasis with alopecia is a rare cutaneous reaction to tumor necrosis factor alpha antagonists. This reaction often reverses with discontinuation of the offending drug and initiation of topical treatments; however, irreversible hair loss may occur
Jeremy Udkoff, Philip R. Cohen
core   +1 more source

Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study

Journal of Clinical Medicine
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population.
T. Holvoet, M. Truyens, Cara De Galan, H. Peeters, F. M. Gismero, A. Elorza, P. Torres, L. Vandermeulen, Aránzazu Jáuregui-Amézaga, R. Ferreiro-Iglesias, Y. Zabana, Laia Peries Reverter, J. Geldof, T. Lobatón   +13 more
semanticscholar   +1 more source

Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report

JPGN Reports, EarlyView.
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling, Shauna Schroeder, Brad Pasternak   +2 more
wiley   +1 more source